COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

41.19

Decreased from previous period

OCF/share 1.25–1.5x 3141.T's 29.23. Bruce Berkowitz would see if the company enjoys cost or pricing advantages.

Free Cash Flow per Share

13.31

Decreased from previous period

FCF/share 50–75% of 3141.T's 19.16. Martin Whitman would wonder if there's a cost or pricing disadvantage.

Capex-to-Operating Cash Flow

67.69%

Increased from previous period

Capex/OCF above 1.5x 3141.T's 34.45%. Michael Burry would suspect an unsustainable capital structure.

Income Quality Ratio (OCF / Net Income)

0.66

Decreased from previous period

Below 0.5x 3141.T's 2.73. Michael Burry would expect an eventual correction in reported profits.

Operating Cash Flow-to-Sales Ratio

3.16%

Decreased from previous period

Below 50% of 3141.T's 6.76%. Michael Burry might see a serious concern in bridging sales to real cash.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

41.19

Decreased from previous period

OCF/share 1.25–1.5x 3141.T's 29.23. Bruce Berkowitz would see if the company enjoys cost or pricing advantages.

Free Cash Flow per Share

13.31

Decreased from previous period

FCF/share 50–75% of 3141.T's 19.16. Martin Whitman would wonder if there's a cost or pricing disadvantage.

Capex-to-Operating Cash Flow

67.69%

Increased from previous period

Capex/OCF above 1.5x 3141.T's 34.45%. Michael Burry would suspect an unsustainable capital structure.

Income Quality Ratio (OCF / Net Income)

0.66

Decreased from previous period

Below 0.5x 3141.T's 2.73. Michael Burry would expect an eventual correction in reported profits.

Operating Cash Flow-to-Sales Ratio

3.16%

Decreased from previous period

Below 50% of 3141.T's 6.76%. Michael Burry might see a serious concern in bridging sales to real cash.

Select Chart Metric: